Vagus Nerve Stimulation

Vagus nerve stimulation delivers electrical pulses to the vagus nerve, the largest parasympathetic nerve and primary carrier of vagal afferent signals to the brainstem nucleus tractus solitarius (NTS). Stimulation modulates downstream serotonergic, noradrenergic, and GABAergic signaling, driving autonomic rebalancing, mood effects, and the cholinergic anti-inflammatory pathway (vagal efferents reduce peripheral cytokine production via acetylcholine on macrophage α7-nAChR). Clinical implanted VNS (Cyberonics, FDA-approved 1997) produces measurable HRV improvement, epilepsy seizure reduction, and antidepressant effects over months to years. Transcutaneous tVNS through the auricular branch (ear) or cervical branch (neck) targets the same pathway non-invasively; HRV improvements are detectable within a single session in multiple RCTs.

Probably, but with a meaningful evidence gap. Clinical-grade transcutaneous VNS has growing RCT support for HRV, depression, inflammation markers, and epilepsy adjunct (6,322 participants studied, zero serious AEs). Consumer devices including Pulsetto (~$300), Xen by Neuvana (~$400), and Truvaga (~$500) target the same vagal branches but use different stimulation parameters (lower current, different waveforms) than the clinical RCT protocols (20-30 Hz, 1-25 mA, 250-500 microsecond pulse width). Direct RCT data for these specific consumer devices is minimal. Most consumer users report modest subjective benefit (improved HRV on wearables, better sleep onset, milder stress response) but not transformative effects. gammaCore (cervical, $600/month, Rx-only) is FDA-cleared for migraine and has proper trial evidence but operates in a different price and access tier.

Auricular tVNS targets the tragus or cymba conchae (inner ear cartilage) with small gel electrodes; cervical tVNS targets the left carotid sheath area on the neck. Standard protocol: 5 to 20 minute sessions, 1 to 2 times daily, typically in evening as wind-down or morning as stress-down-regulation. Session intensity is adjusted individually; start at lowest perceptible pulse and increase to comfortable tingling without pain. Current community best practices: combine with slow breathing (4-7-8 or box breathing) during sessions to amplify parasympathetic signal. Track HRV on wearable (WHOOP, Oura, Apple Watch) over 2 to 4 weeks to assess response. Non-responders are typically those with already-high baseline vagal tone. Electrode hygiene important; replace pads per manufacturer guidance.

Transcutaneous VNS has an exceptional safety record. Across 6,322 participants in clinical studies, there are zero confirmed serious adverse events. The incidence of any adverse event is 12.84 per 100,000 person-minute-days. Most common complaints: ear discomfort at electrode site, mild headache, local tingling. All transient and resolve after the session. No systemic side effects reported. Implanted VNS carries surgical risks (infection 2.6%, voice alteration 45.5%), but these are irrelevant to the consumer tVNS use case. Contraindications: pacemaker, bilateral vagotomy, carotid sinus hypersensitivity, severe bradycardia. Drug interactions with beta-blockers, non-DHP calcium channel blockers, and digoxin warrant awareness due to additive bradycardia potential but are not absolute contraindications. No catastrophic risk floor triggered for transcutaneous use.

Overlapping but distinct tools for autonomic regulation. HRV biofeedback (Inner Balance, HeartMath) teaches voluntary control of breathing-cardiac coupling; free or low-cost, skill-building, durable gains. Slow breathing (4-7-8, box, Wim Hof) activates vagal tone without equipment; $0, always available, no device dependency. Cold exposure (face plunge, cold shower) produces powerful acute vagal response via mammalian dive reflex. tVNS delivers direct electrical stimulation targeting the same pathway; passive, measurable via HRV, but requires device and electrode placement. Implanted VNS is for specific clinical indications (epilepsy, depression) not lifestyle use. For most biohackers: start with breathwork and HRV biofeedback (free, durable), add cold exposure (cheap), and consider tVNS as supplemental if underlying autonomic dysregulation persists. Nick uses tVNS alongside breathwork and HRV; it is not a breathing replacement.

Six populations should avoid or use with caution. Pacemaker or implantable cardioverter-defibrillator (electromagnetic interference risk). Bilateral vagotomy (nerve absent, no target). Severe carotid sinus hypersensitivity (excessive vagal response risk). Severe bradycardia or second/third-degree heart block (additive bradycardia risk). Concurrent high-dose beta-blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), or digoxin (additive bradycardia; consult prescriber). Pregnancy (safety data thin though no mechanism suggests harm). Relative cautions: active severe mental illness with autonomic instability, history of vasovagal syncope (start low and titrate), and recent cardiac event. Consumer tVNS is NOT contraindicated by typical biohacker health profiles; most users can proceed safely.